Status:
ACTIVE_NOT_RECRUITING
Multimodal Imaging of MS Reveals the Smoldering Inflammation
Lead Sponsor:
Turku University Hospital
Conditions:
Multiple Sclerosis
Eligibility:
All Genders
18-70 years
Brief Summary
To evaluate active MS plaque evolution with conventional MRI, QSM-post processing, TSPO-PET imaging and P2X7-PET imaging.
Detailed Description
Objective: To establish the QSM-MRI-method as a part of MS-patient research protocol in TPC and to quantify the time and space dependent correlation of QSM-MRI signal and PET-imaging signal with both ...
Eligibility Criteria
Inclusion
- Inclusion Criteria
- Active MS-patients:
- Informed consent form
- At least one 0,5 cm diameter active gadolinium enhancing lesion detected lately
- Diagnosed MS-disease according to McDonald criteria
- SPMS patients
- Informed consent form
- Diagnosed MS-disease according to McDonald criteria
- SPMS disease
- Healthy controls:
- Informed consent form
- healthy
- age and sex matched with MS-patients in RRMS and SPMS groups
- Exclusion Criteria
- MS-patients:
- Patients suffering from another brain disease or other autoimmune disease in addition to multiple sclerosis
- Steroid treatment 4 weeks prior to the scan
- Significant pathology in the MRI scan other than MS-related lesions
- Patients suffering from claustrophobia or panic disorder, or patients who have exhibited hypersensitivity of PET markers (practical obstacle to the scan)
- Exposure to experimental radioactivity in the last 12 months such that the dosimetry threshold would be exceeded due to participation in the study
- Age over 70
- Healthy controls:
- autoimmune disease, CNS disease or other serious disease
- Steroid treatment 4 weeks prior to the scan or other regular medication
- persons suffering from claustrophobia or panic disorder, or persons who have exhibited hypersensitivity of PET markers (practical obstacle to the scan)
- Exposure to experimental radioactivity in the last 12 months such that the dosimetry threshold would be exceeded due to participation in the study
- Age over 70
Exclusion
Key Trial Info
Start Date :
February 27 2019
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 1 2025
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT04126772
Start Date
February 27 2019
End Date
December 1 2025
Last Update
January 15 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Turku PET Centre
Turku, Southwest Finland, Finland, 20520